Zydus Life Settles Bladder Drug Dispute with Astellas for $120 Million

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Zydus Life Settles Astellas Bladder Drug Patent Dispute for $120 Million

The announcement comes days after local peer Lupin decided to settle its dispute with Astellas over the same drug for $90 million. Reuters

M

Moneycontrol•12-02-2026, 11:11

Zydus Life Settles Astellas Bladder Drug Patent Dispute for $120 Million

•Zydus Lifesciences and its US unit will pay $120 million to Astellas Pharma to settle a patent dispute.
•The dispute concerned Astellas' bladder disorder drug Mirabegron.
•Zydus will also pay a pre-paid per-unit licensing fee on sales of its generic Mirabegron in the US until September 2027.
•The settlement allows Zydus to continue marketing its generic Mirabegron in the United States.
•This follows a similar $90 million settlement by Lupin with Astellas over the same drug, potentially limiting competition for Zydus and Lupin.

Read Full Article on Moneycontrol in English

✦

More like this

✦

More like this

Representational image (Image: News18)

Zydus to Pay Astellas $120 Million to Settle Patent Dispute Over Bladder Drug

The BMC plans to start 25 more Aapla Dawakhana and three physiotherapy centres in the next financial year.

Zydus Lifesciences settles Mirabegron patent dispute with Astellas for $120 mn

Lupin Settles Mirabegron Patent Dispute with Astellas for $90 Million

Lupin Settles Mirabegron Patent Dispute with Astellas for $90 Million

Zydus Lifesciences

Zydus Lifesciences Shares Surge on USFDA Approval for Ammonium Lactate Cream

Representational image (Image: News18)

Alembic Pharma gets USFDA nod for generic anti-fungal solution

Late sex offender Jeffrey Epstein. (Image: Reuters)

Epstein Estate to Pay $35 Million Settlement to Victims in New Lawsuit